Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. - Wikidata - wikimedia - TriplyDB

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

http://www.wikidata.org/entity/Q38066860

about

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect New antibody approaches to lymphoma therapy Treatment of pediatric acute lymphoblastic leukemia.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Adoptive immunotherapy for cancer or viruses.Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking.CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.Medical management of side effects related to CAR T cell therapy in hematologic malignancies.The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.The biological basis and clinical symptoms of CAR-T therapy-associated toxicites

P2860

Q26773309-A379F77B-6AA5-4D65-AEFE-19F4BDD6EEEB Q26775720-6B221DF0-CBBB-438C-9A7E-FFD133278C06 Q26781831-A1CE2C3B-C69E-48D4-8021-0A2949F1E881 Q26826830-EC04A150-EF1F-4726-B494-D7987BB7E446 Q27022373-B299D238-051A-4943-AE3D-8E131B837FB3 Q35196702-0FC8D44C-8F14-431E-AD5B-EDDEB02AAC80 Q37579561-77029269-69B2-41C4-B3EB-30B8BD47D2FF Q37609801-BE601875-5A05-41A8-8763-6BD4C6051EEE Q38178359-BDCE5EE8-BAA7-45FF-83CB-632037634196 Q38666579-55A1522E-95AC-435F-8683-235054A5201D Q39031463-320CEC9F-E2DE-41B1-A7AA-BE708DBC9D74 Q39122928-E3C33FF0-7D74-446B-9E75-E008B287DA92 Q41208517-989F114D-5130-49EC-A451-BFCD5D89A6C9 Q47809709-8ABE66EF-A140-48D4-8E94-C66F587F94C2 Q50531950-FC0E9A3E-B1EA-49CA-B2BE-6D305EA490B2 Q58765358-F0382184-D0EF-40D2-ADC1-41DAAB8C2E5A

P2860

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

http://www.wikidata.org/entity/Q38066860

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

@en

type

label

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

@en

prefLabel

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

@en

P1433

Q38066860-B1BAC960-10DF-4060-B5CC-961BA54E94F5

P1476

Q38066860-431F07DF-6C76-4D68-82B9-9AAEF40ED13F

P2093

Q38066860-4B9892A4-0445-4C4B-82AA-CF99CC31D9B3

Q38066860-7D9E75FA-2FB4-42B4-941A-DD650934F055

P2860

Q38066860-03CCC0D2-61A4-4605-A970-73D192F27C75

Q38066860-04BE8EEB-FE84-454F-94FB-0A2A3F22BAC4

Q38066860-054AD658-CE53-43EB-85BC-0ED01764DB77

Q38066860-059DFE35-2BDC-4336-B626-F1572C6629CC

Q38066860-0895F909-FDB7-423F-AF62-FB94CA70A130

Q38066860-09E521F6-EB9C-45EB-932F-AE7D44C61A42

Q38066860-14678F2E-E6F3-466B-AD51-053078C08735

Q38066860-15FD20A7-4A21-4713-A931-F9297659112E

Q38066860-19EC6B4F-850B-4B77-8680-F8FA7F173CB2

Q38066860-1C49764F-A875-4F33-B3C9-D7D561869D48

P304

Q38066860-7594FA05-47C5-412D-9A2A-DD06433269FA

P31

Q38066860-2f525155-4ae7-4ab1-b171-db80fd710772

Q38066860-69EAE56A-9578-43D7-9565-320F9A262324

P356

Q38066860-0CD744C6-4B08-4057-A502-CA952944B3FD

P478

Q38066860-729D6A64-7EDE-4BC7-8E0E-3D1968DF8A6D

P577

Q38066860-08A53991-6DBC-4121-9EB9-3F0B44B295EC

P698

Q38066860-99C1C34D-2E69-418C-829E-E7779C70BBCF

P921

Q38066860-8A1E97FA-F762-4237-8BD0-12F30A0B4F66

P932

Q38066860-E0D708B7-527A-41E9-8AE0-123E0235486E

P356

ASHEDUCATION-2012.1.143

P1433

Hematology / the Education Program of the American Society of Hematology

P1476

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

@en

P2093

Kevin J Curran

http://www.w3.org/2001/XMLSchema#string

Renier J Brentjens

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Treating childhood acute lymphoblastic leukemia without cranial irradiation

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

P304

143-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/ASHEDUCATION-2012.1.143

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23233573

http://www.w3.org/2001/XMLSchema#string

P921

P932

5536093

http://www.w3.org/2001/XMLSchema#string